-
Evaluating Risk: Gilead Sciences, Biogen and Celgene
biospace
April 08, 2018
When it comes to large-cap biotech companies,?Gilead Sciences,?Biogen?and?Celgene?are always worth investment consideration, but are not without their risks.?
-
Biogen acquires Schizophrenia investigational drug candidate form Pfizer
biospectrumasia
March 16, 2018
The purchase will include an upfront payment of $75 million with up to $515 million in additional development and commercialization milestone payments
-
Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Me
biospace
March 16, 2018
Biogen?(Nasdaq: BIIB) Italy (March 15-18, 2018). AAT-AD/PD is a new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer’s Therapy and AD/PD?.
-
Biogen to acquire first-in-class Phase IIb ready asset for cognitive impairment
cphi-online
March 14, 2018
PF-04958242 is an AMPA receptor potentiator designed to facilitate neurotransmission.
-
Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associate
biospace
March 13, 2018
Biogen?Inc. (Nasdaq: BIIB) announced today an agreement to acquire from?Pfizer Inc.?(
-
Biogen Buys Pfizer's PhII-ready Schizophrenia Asset
biospace
March 13, 2018
Biogen?is?buying?Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
-
Biogen and AbbVie Voluntarily Pull Multiple Sclerosis Drug Off the Market
biospace
March 05, 2018
Biogen?and?AbbVie?have voluntarily?pulled?their Zinbryta for relapsing multiple sclerosis (MS) off the market after safety concerns.
-
Study Shows Biogen’s MS drug Tecfidera could make cancer-killing viruses more potent
fiercebiotech
January 26, 2018
The Cancer-killing“oncolytic” viruses, which was derived from herpes, made their way into oncology practices in 2015 with Amgen’s melanoma drug Imlygic being approved.
-
Pfizer's Biosimilar of Biogen, Roche's Rituxan Meets Main Goal in Study
biospace
January 25, 2018
?Pfizer? today announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera?(rituximab-EU), met its primary endpoint. PF-05280586 is being developed by Pfizer as a potential biosimilar to Rituxan?/MabThera?1.
-
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018
biospace
December 22, 2017
Biogen?(NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2017 financial results on Thursday, January 25, 2018, before the financial markets open.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
